Oramed plans new U.S. Phase 3 oral insulin trial after subpopulation analysis; JV with HTIT with $70M investment

ORAMED PHARMACEUTICALS INC.

HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.
Oramed to initiate new Phase 3 U.S. oral insulin trial later 2024 under differentiated protocol after FDA discussions; earlier Phase 3 missed endpoints.
Scilex issued $101.875M secured note to Oramed at SOFR+8.5%; repayment began Dec 2023; warrants for 13M Scilex shares at $0.01.
Acquired PeriTech film-forming technology for topical/dermatology; entered exclusive licensing deal for royalty on net sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.